Second 'JOURNEES DES CORDELIERS' 2003 to take place in Paris, Oct. 1-3, under the joint organisation of Pierre & Marie Curie University - Paris VI and IDM

PARIS--(BUSINESS WIRE)--July 15, 2003--The second "Journees des Cordeliers" will take place in Paris, France between October 1-3, 2003, under the joint organisation of Pierre & Marie Curie University - Paris VI and the biopharmaceutical company, IDM (Immuno-Designed Molecules). Founded in 1993, IDM is one of the European leaders in cellular immunotherapy in the fight against cancer.

This conference will give internationally renowned doctors and scientists a chance to present their work concerning the latest advances in immunology and their applications in the treatment of cancer.

BizVantage – Beyond the news - a realtime Net clipping service: for business, investment or technology.
Try the free, no-hassle 6 month trial!

A scientific event of international importance, this conference will unite 150 researchers and clinicians from three continents. It is the result of a successful union between the world of academic research and that of applied research, the public sector and business.

The main themes to be discussed during the working sessions are tumors and their microenvironment and future therapeutic approaches. A presentation of scientific posters is scheduled for October 2nd. A prize of 3000 EUR for the best poster will be awarded by the "Journees des Cordeliers" scientific committee.

Registration and information:

www.idm-biotech.com/EventsCal.htm#Journee

IDM - The Immunogenics Company(R) IDM is a leading biopharmaceutical company developing a new family of immunotherapy products called Cell Drugs to fight cancer and other life-threatening diseases. IDM applies its proprietary technologies to selectively isolate, engineer, expand and activate specific cell populations which are involved in therapeutic vaccination. The Company's products are designed to boost the immune system, destroy residual tumor cells, and immunize patients to prevent tumor recurrence. IDM's most advanced product is in Phase III for the treatment of ovarian cancer.

For more information, please visit IDM's Web site, http://www.idm-biotech.com

IDM Paris Headquarters   172 rue de Charonne
                         75011  Paris  FRANCE
                   tel   +33 (0) 1 40 09 04 11
                   fax   +33 (0) 1 40 09 04 25
                  e-mail idm@idm-biotech.com